MediWound (NASDAQ:MDWD) Upgraded to “Sell” by StockNews.com

StockNews.com upgraded shares of MediWound (NASDAQ:MDWD) to a sell rating in a report released on Wednesday morning.

Separately, HC Wainwright reiterated a buy rating and issued a $28.00 price objective on shares of MediWound in a research report on Friday, March 22nd.

MediWound Trading Down 6.3 %

Shares of MDWD opened at $17.75 on Wednesday. The firm’s 50-day moving average is $16.27 and its two-hundred day moving average is $12.62. MediWound has a twelve month low of $7.10 and a twelve month high of $19.86. The firm has a market capitalization of $168.48 million, a P/E ratio of -23.05 and a beta of 0.81.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. The business had revenue of $5.34 million for the quarter, compared to analysts’ expectations of $5.33 million. MediWound had a negative return on equity of 20.22% and a negative net margin of 35.94%. Analysts predict that MediWound will post -1.93 EPS for the current year.

Institutional Investors Weigh In On MediWound

Institutional investors and hedge funds have recently bought and sold shares of the stock. Janney Montgomery Scott LLC acquired a new position in shares of MediWound in the first quarter worth $427,000. Silverberg Bernstein Capital Management LLC acquired a new position in MediWound in the 4th quarter valued at about $803,000. Yelin Lapidot Holdings Management Ltd. purchased a new position in MediWound in the 3rd quarter valued at about $917,000. Sargent Investment Group LLC boosted its stake in shares of MediWound by 7.0% during the 4th quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock worth $1,111,000 after purchasing an additional 7,125 shares during the last quarter. Finally, Essex Investment Management Co. LLC grew its holdings in shares of MediWound by 241.6% during the first quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock worth $1,888,000 after buying an additional 93,705 shares in the last quarter. Hedge funds and other institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.